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Abstract 
Typhoid fever is endemic in the Mediterranean North African countries (Morocco, Algeria, Tunisia, Libya, and Egypt) with an estimated 
incidence of 10-100 cases per 100,000 persons. Outbreaks caused by Salmonella enterica serovar Typhi are common and mainly due to the 
consumption of untreated or sewage-contaminated water. Salmonella enterica Paratyphi B is more commonly involved in nosocomial cases 
of enteric fever in North Africa than expected and leads to high mortality rates among infants with congenital anomalies. Prevalence among 
travellers returning from this region is low, with an estimate of less than one per 100,000. Although multidrug resistant strains of Salmonella 
Typhi and Paratyphi are prevalent in this region, the re-emergence of chloramphenicol- and ampicillin-susceptible strains has been observed. 
In order to better understand the epidemiology of enteric fever in the Mediterranean North African region, population-based studies are 
needed. These will assist the health authorities in the region in preventing and controlling this important disease. 
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Introduction 
Enteric fever is an acute systemic infection 
caused mainly by Salmonella enterica serotype Typhi 
(S. Typhi) [1]. Salmonella enterica serotype 
Paratyphi A, B, and sometimes C (S. Paratyphi A, B 
and C) cause similar but less severe disease 
compared with S. Typhi [2].  As recently as the year 
2000, typhoid fever has been estimated to cause 21.6 
million illnesses and 216,500 deaths among children 
and young adults worldwide [2-6]. These data 
represent the tip of the iceberg since the real burden 
of enteric fever remains almost unknown in different 
developing countries where the disease is a serious 
public health problem. 
The aim of this review is to provide an overview, 
on the basis of limited data available in literature, 
with respect to the epidemiology, spread of 
antimicrobial resistance, and treatment practices of 
typhoid fever in the Mediterranean North African 




Little data is available regarding the incidence of 
typhoid fever in the Mediterranean North African  
 
countries, mainly due to a lack of or insufficient 
epidemiological surveillance activities and limited 
diagnostic facilities. In order to facilitate the interest 
of under-represented nations and their problems, an 
online Salmonella Network [7], which links with 
activities conducted by the Journal of Infection in 
Developing Countries (JIDC), has recently been 
established. This network encourages the sharing of 
data and results from developing areas such as North 
Africa and provides an opportunity to create a 
collection of clinical Salmonella strains for further 
research. Areas of potential interest are as follows: 1) 
dissection of mechanisms of antibiotic resistance, 2) 
pathogenicity, 3) epidemic potential and 4) infection 
control. A number of scientists from North African 
countries including Morocco, Tunisia, Algeria, and 
Libya are now part of this educational and scientific 
activity. 
According to a recent surveillance (2000-2002) 
supported by the World Health Organization (WHO) 
S. Typhi ranked as the third (8%) most prominent 
Salmonella spp. isolated in Africa after S. 
Typhimurium (26%), and S. Enteritidis (25%) [8]. 
 

















This study was extended through the WHO Global 
Salm-Surv program until 2005 [9]. During this 
period, S. Typhi dropped to sixth place overall (5%) 
following S. Typhimurium, S. Enteritidis, S. Isangi, S. 
Livingstone, and S. Corvalis. At present,  typhoid is 
considered an endemic disease in Mediterranean 
North African countries with estimated medium 
incidence of 10 to 100 cases per 100,000 persons 
(Table 1) [2,3,10]. The most important point is that 
epidemiological reports, not always based on 
population studies and outbreak descriptions, have 
been sporadically reported mainly in national rather 
than international publications. 
 
Libya 
In Libya, a comprehensive study was conducted 
on 30,165 patients who were hospitalized with acute 
diarrhoea during 1975-1980 [11]. A low prevalence 
of S. Typhi and S. Paratyphi in stool samples of 
patients was shown. Among different serotypes of 
Salmonella identified in 7,560 patients, 81 were 
identified as S. Typhi, 3 S. Paratyphi A and 4 S. 
Paratyphi B. In recent years, an increased rate of 
typhoid has been observed. For example, according 
to information resources of the Libyan Center for 
Information and Documentation (CID) of the 
Secretary of Health and Environment, the incidence 
rate for the years 2004, 2005 and 2006 were seven, 
21 and 16/100,000 persons/year respectively [12-14]. 
The diagnosis of the cases included in the previously 
mentioned studies was based only on clinical features 
and further confirmation by laboratory testing was 
required. The significant increase in the incidence 
over this period is probably due to the improvement 
of the data reporting system and improved 


















In order to establish the etiology of enteric 
infections with a particular emphasis on the 
identification of Salmonella spp and S. Typhi in 
Egypt, several studies have been performed. Most of 
these studies have been conducted in cooperation 
with the Egyptian Ministry of Health and Population 
(MOHP) and the U.S. Naval Medical Research Unit-
3 (NAMRU-3), often in partnership with the US 
Center for Diseases Control and Prevention (CDC). 
The first study that attempted to establish the 
incidence of enteric fever in Egypt was conducted 
during a vaccination campaign in 1972-1973; a high 
incidence of cases (209/100,000 persons [15]) was 
reported. An additional surveillance study (1978-
1981) in the same social context, examining school-
aged children in Alexandria, reported a lower 
incidence of 48/100,000 [16,17]. 
Wasfy and co-workers [18] conducted a study on 
stool samples collected from 6,278 young patients 
(mean age of 14.1 years) admitted to the Abbassia 
Fever Hospital in Cairo from 1986 to 1993 with acute 
enteric infections. Salmonella spp was isolated from 
465 patients in this cohort. The majority of the 
isolated strains (53%) were S. Typhi, while only 3% 
were S. Paratyphi A. The peak of cases was observed 
during February-March, June-July, and October-
November. 
An outbreak of typhoid fever caused by a 
chloramphenicol resistant strain of S. Typhi occurred 
in Gharbeya Governorate in 1990, involving 90 
children and 43 adults [19]. Although, the source of 
infection was not confirmed, consumption of 
contaminated food was hypothesized as the main 
cause of infection due to the involvement of children 




Figure 1. Map of Mediterranean North Africa. 







A study performed in the period from 1999 to 
2003 by a sentinel surveillance network involving 
several hospitals in the country demonstrated that S. 
Typhi and Brucella spp were the most common 
infective agents of acute febrile illness. Particularly S. 
Typhi was detected in blood samples from 5% of the 
patients under study [20].  
At the beginning of the second millennium, the 
incidence of typhoid fever was estimated to be 15 
cases per 100,000 persons on the basis of the 
Egyptian National Syndrome-Based Surveillance [3].  
Between 2001 and 2005, several authors [21,22] 
reported a decrease of cases to 13 per 100,000 in 
different districts of Egypt. However, these data 
included mainly clinical notifications with only a low 
percentage confirmed by laboratory culture methods. 
Recently, a laboratory-based surveillance project 
was conducted in Upper Egypt involving governorate 
health officers, clinicians and several health care 
centres (from the Regional Hospital to the rural 
health units and primary care physicians). The results 
from this study showed that the incidence of typhoid 
fever was 59/100,000 persons/year [3]. This number 
was higher than that previously reported from studies 
based on hospital syndromic surveillance. Despite 
this finding, Egypt remains a country with 
intermediate incidence of one to 100 per 100,000 
cases of enteric fever, below nations such as India 
and Indonesia which claim more than100 cases per 
100,000 persons [21]. These results also indicate that 
the majority of typhoid cases (71%) were managed 
by a primary care facility, an observation that may 
demonstrate the importance and the efficacy of these 
structures as a first barrier to combat this disease. 
Interestingly S. Typhi was isolated in blood culture in 
5% of cases of all 1,815 patients evaluated with 
fever, particularly in school-aged children. We 
believe that this research approach provides a more 
realistic picture and is closer to the real burden of 
typhoid fever in Egypt. Furthermore, the 
methodological approach reported in this study [3] 
could be an example of an accurate research and 
public health activity and can be a model for other 
developing countries, especially those with the 
involvement of the large health structures. 
 
Tunisia 
In 1977 and 1982, the National Center of 
Salmonella at the Institute Pasteur, Tunis,  identified 
1,715 Salmonella isolates from throughout Tunisia;  
S. Typhi and S. Paratyphi were the most predominant 
(99.6%) isolates [10].  
As predicted, contaminated drinking water was 
the main source of the disease’s transmission, and 
infant septicemia was a major cause of death in one 
third of the cases [23]. In 1989, an incidence of about 
6 cases per 100,000 per year was reported [24]. 
During the summer of 1999, an outbreak of 
typhoid fever occurred in and around the coastal city 
of Sousse. Samples from patients admitted to Farhat 
Hached Sousse Hospital and M'saken Hospital were 
examined. Ribotyping used to identify genetic 
similarities among the isolates demonstrated that 22 
of the 24 isolates were indistinguishable [25], an 
indication that this outbreak may have originated 
from a single source. 
Recently, Ben Aissa et al. [26] reported the first 
investigation on the trends of S. enterica serotypes 
isolated from different sources all over Tunisia 
during a decade (1994-2004). Isolates were collected 
during a national surveillance programme conducted 
by the National Centre of Enteropathogenic Bacteria, 
Institute Pasteur, Tunis (a member of WHO Global 
Salmonella Surveillance Program). S. Typhi was 
among the eight most frequently isolated Salmonella 
serotypes identified, detected in 1% of stool samples 
and 39% of blood samples examined [26]. Peak 
isolation rates were detected in 1999 and 2004, which 
corresponds to two outbreaks that occurred in Sousse. 
The first was detected in a hospital and the second 
was detected in the community. 
Another group of investigators [27] studied two 
successive outbreaks of typhoid fever that were 
reported in 2004 and 2005 in southeast Tunisia. A 
total of 86 isolates of S. Typhi were recovered. All 
isolates were susceptible to ampicillin, 
chloramphenicol, trimethoprim-sulphamethoxazole 
and ciprofloxacin. Pulsed field gel electrophoresis 
using the restriction enzyme XbaI indicated that a 
single clone appeared to be responsible for the 2004 
outbreak. Interestingly, investigation of the 2005 
outbreak revealed isolates possessing five different 
XbaI profiles, although the 2004 outbreak pattern 
predominated. This finding indicated that several 
Country Incidence/100,000 References 
Algeria 3-22 34 
Egypt 13-59 3, 22 
Libya 7-21 12,13,14 
Morocco 8-17 21,22,32 
Tunisia 1-6 24,28 
Table 1. Incidence of typhoid fever in North African Countries. 




strains were involved in the second epidemic episode. 
The 2006 Bulletin of the Ministry of Health showed 
an incidence of typhoid fever of about 1 case per 
100,000 per year in Tunisia [28]. However, there are 
only scattered reports directly examining the 
incidence of typhoid fever in Tunisia. More 
comprehensive surveillance data are necessary to 
evaluate the actual burden of disease and relevant 
risk factors in the country. 
 
Morocco 
S. Typhi and S. Paratyphi are endemic in 
Morocco [29,30]. Recent studies from national and 
international agencies such as the National Institute 
of Hygiene (Rabat) and the WHO Global Salmonella 
Surveillance Program have provided useful 
epidemiological data regarding the prevalence of S. 
Typhi in Morocco [31]. In 1999, S. Typhi was the 
most common isolate of Salmonella; however, by the 
year 2000 it had dropped to the third most common 
isolate. No cases of typhoid were reported in 2001, 
and a year later, it was only the fourth most 
commonly isolated Salmonella serotype. In 2003, 
only S. Paratyphi B was isolated. According to the 
data published by Ministry of Health, typhoid fever 
was observed in 8-17 cases per 100,000 per year 
from 1993-1999, [32] and recent data gives an 
estimate of 8 cases per 100,000 [21,22]. 
 
Algeria 
The prevalence of Salmonella infections in 
Algeria was first reported by Guechi and Hamza [33], 
covering the years from 1986 to 1990. S. Typhi was 
the dominant serotype, claiming 98% of the 3,340 
clinical isolates of Salmonella spp recovered. 
However, from 1985 to 2005, the National Institute 
of Public Health reported only 3-22 cases of typhoid 
fever per 100,000, [34] which is similar to what has 
been reported from Middle-Eastern countries [35]. In 
Algeria, the highest incidence rates for enteric fever 
are reported during the hot summer months and 
among school-aged children (i.e. from 5 to less than 
20 years of age) [32]. In addition, available data from 
this geographic area suggested that typhoid fever 
occurs more commonly among males than females 
[36]. 
In January 1996, a typhoid fever outbreak with 
more than 900 suspected cases was reported in Ain 
Taya, located 20 km East of Algiers. The outbreak 
resulted from contamination of the village water 
reservoirs by sewage water [37]. Another outbreak 
caused by the use of untreated water was reported in 
2004 in Batna province with 328 typhoid fever cases; 
38 patients required hospital care [38]. 
 
Complications of typhoid fever 
Benkortibi et al. [39] studied 1,310 children with 
typhoid fever admitted to El Kettar Hospital in 
Algeria during a 16-year period from January 1975 to 
December 1990. In 9% of these children, one or more 
gastrointestinal, neurological or cardio-vascular 
complications were identified. Similarly, a high 
percentage (13%) of complications was reported in 
Moroccan children admitted to a Casablanca hospital 
from January 1980 to December 1991 [40]. Most 
frequent complications were neurological (46%), 
gastrointestinal (35%), and hematological (16%). 
Interestingly it was observed that female gender, poor 
hygiene conditions, and digestive parasitosis were the 
most important determining factors of complicated 
typhoid fever in the children studied [40]. Similar 
complications including lower gastrointestinal 
bleeding, relapse, uraemia and icterus were observed 
during an outbreak of typhoid fever among children 
in Egypt [19]. A rare complication of typhoid fever, 
splenic abscess, was reported in Algerian patients 
with acute lower thoracic pain by using abdominal 
ultrasound [41].  
 
Studies from several developing countries have 
shown a positive association between the chronic 
typhoid carrier state and carcinoma of the gallbladder 
[42-44]. Recently, Nath et al. in India [45], using 
nested PCR for the flagellin gene specific sequences 
of S. Typhi, detected the organism in 67.3% of 
patients with gallbladder carcinoma and in 8.2% of a 
healthy population not matched for age and sex (P < 
0.001). However, no data is available regarding the 
association of typhoid carriage and gallbladder 
carcinoma in the Mediterranean North Africa region. 
 
Nosocomial (hospital-acquired) typhoid and 
paratyphoid fever 
Although S. Typhi and S. Paratyphi are not 
common causes of nosocomial infections, several 
hospital-acquired infections due to both organisms 
have been described in North Mediterranean Africa 
with high mortality rates in newborns. During the 
period from August 1994 to June 1995, stool, blood, 
and CSF samples were collected from 468 infants (1 
to 35 days old) who developed watery diarrhoea 4 to 
18 days after admission to a neonatal unit at the 
Children's Hospital of Benghazi in Libya [46]. 
 




Salmonellae were detected in 8% (36) of the 
collected samples, with 26 isolates being S. Paratyphi 
B and 10 S. Typhi. Of the laboratory-confirmed 
Salmonella-positive infants, eight died and six had 
congenital anomalies. A strong association between 
bottle feeding and infection was observed. The 
majority of the infections were acquired during the 
hot months of the year (June-September). In another 
study also conducted in Benghazi in the period from July 
2000 to June 2001, forty-one Salmonella strains 
isolated from stool samples of children aged between 
3 days and 12 years were serotyped. Of these, seven 
were S. Paratyphi B and two S. Typhi. The 
investigators reported that all the S. Paratyphi B 
isolates were nosocomially acquired [47]. 
 
 
Typhoid and paratyphoid fever in travellers 
to North Africa 
Enteric fever is rare in industrialized countries; 
however it does present among travellers returning 
from areas of endemicity [48]. Therefore, it is 
important to see the risk for travellers acquiring 
enteric fever during their visits in this region. 
Previous studies have reported a low prevalence of 
typhoid and paratyphoid among travellers to North 
Africa; however, for travellers planning to remain in 
the region for six months or longer, vaccination 
against typhoid is recommended by the WHO and the 
CDC (http://www.who.int/ith/en/ and 
http://wwwn.cdc.gov/travel/). 
 
An Australian study [49] reviewed 232 patients 
(15% travelled to Africa) admitted to a tertiary-care 
hospital for management of febrile illness acquired 
overseas. Typhoid fever was found in eight (3.5%) 
patients and was more common in travellers returning 
from a trip to Asia. A larger clinical-based sentinel 
surveillance study analyzing 17,353 sick travellers 
indicated that typhoid fever was one of the primary 
contributors to systemic febrile illness among 
travellers returning especially from south central Asia 
but not from other regions (including North Africa) 
[50]. Similar findings were reported for Swedish and 
French travellers [51,52]. Incidence of typhoid fever 
in Israeli and American travellers to Egypt and 
Morocco is estimated at 0.3 and 0.7 per 100,000 
visits [21,22], while the rate of infection in all 
travellers to the Indian subcontinent was 17.3 per 
100,000 visits. Although much evidence suggests the 
low risk of typhoid fever for travellers to North 
African countries, it is important for tourists to avoid 
eating and drinking contaminated food and water, the 
typical transmission factors. 
 
Antimicrobial resistance and treatment 
Since 1984, several investigators reported S. 
Typhi resistance to one or more antibiotics [53,54]. 
In Algeria the first S. Typhi strain with multidrug 
resistance (MDR) to ampicillin, chloramphenicol, 
streptomycin, and kanamycin was reported in 1973 
linked to the presence of a plasmid [55]. In order to 
explore the emergence of MDR Salmonella strains in 
the country, 752 S. Typhi and S. Paratyphi strains 
isolated during the period between October 1973 and 
August 1974 were tested for their resistance to 
different antibiotics. All the examined strains were 
susceptible to antibiotics used in the study except one 
S. Typhi isolate. This plasmid-bearing strain was 
MDR, including to drugs that are commonly used to 
treat typhoid fever [56].  However, in a study with a 
larger number of S. Typhi (5,940 strains), S. 
Paratyphi A (123 strains) and S. Paratyphi B (115 
strains) isolated between 1979 and 1984, no 
resistance was found while seven strains isolated in 
the middle of 1973 to December 1978 were resistant 
to some antibiotic indicating that the spread of MDR 
strains was still limited [57]. 
A paper published in 1982 reported studies in 
which all S. Typhi (392 strains) isolated from blood 
were susceptible to ampicillin and tetracycline [58]. 
These studies showed that, although sporadic strains 
were resistant to some antibiotics, MDR strains were 
not spread at that time in Algeria.  
In 1981, Sippel et al. [59] reported the isolation 
of a chloramphenicol-resistant S. Typhi strain 
isolated from the stool of a patient with typhoid fever 
in Upper Egypt. Nearly a decade later, Mikhail et al. 
[60] isolated for the first time MDR 
(chloramphenicol, ampicillin and trimethoprim-
sulphamethoxazole) S. Typhi from the blood of an 
Egyptian patient suffering of typhoid fever. 
During the last 15 years a steady increase of 
MDR S. Typhi in some North African countries has 
been  observed. In 1993, El-Mahdy et al. [61], in 
Mansoura, Egypt, examined blood cultures obtained 
from 42 Egyptian children (aged 4 to 12 years) 
clinically suspected of typhoid fever, with no 
response to antibiotics treatment for two weeks. Only 
nine (21%) children were positive for Salmonella 
(five S. Typhi, two S. Paratyphi A and two S. 
Paratyphi B) and two strains were MDR (one S. 
Typhi and one S. Paratyphi A). However, in a phage-
Vi surveillance-based study conducted in the same 




year at Alexandria Fever Hospital (Alexandria, 
Egypt), 43% of the isolated S. Typhi strains were 
MDR. Moreover, the identified phage types were E2 
or D1-N [62] which are different from the phage type 
E1 that dominates in the Indian subcontinent [63,64]. 
It is not known whether S. Typhi E2 and D1-N are 
also the dominant types in the other North African 
countries. 
Wasfy et al. [18] described the resistance of 537 
S. Typhi isolates identified in Egypt. MDR was 
detected in more than 71% of the isolates, 
particularly to the most commonly used antibiotics 
for the treatment of typhoid fever (i.e. ampicillin, 
chloramphenicol and TMZ-SMZ). In addition, the 
authors demonstrated that the resistance was 
associated with the presence of a transferable 120 
MDa plasmid. However, the S. Typhi isolates were 
sensitive to amikacin, aztreonam, ceftriaxone, 
gentamicin and nalidixic acid, suggesting the possible 
use of aztreonam and ceftriaxone as alternative 
therapeutic drugs of choice for the treatment of 
infections due to MDR S. Typhi strains. 
In a population-based surveillance study 
conducted in 2002 in Fayoum, Egypt, the majority 
(65%) of S. Typhi isolates were resistant to all first-
line antibiotics used in the treatment of the disease, 
and 25% of the isolates were classified as MDR [3]. 
Also in Egypt, Abdel Wahab and co-workers 
reported MDR S. Paratyphi A [65].  
MDR S. Typhi (strain 302) isolated from blood 
culture in the Department of Infectious Diseases of 
Rabta Hospital, Tunis, was found resistant to 
amoxicillin, streptomycin, tetracycline, 
chloramphenicol, and trimethoprim-
sulphamethoxazole (TMZ-SMZ) [66]. The 
conjugative experiments indicated that resistance was 
related to a transferable plasmid of about 40 kb. In 
addition, the S. Typhi isolate was found positive for 
TEM-1 beta-lactamase. 
The majority of S. Typhi and S. Paratyphi B 
isolated from infants with hospital-acquired typhoid 
and paratyphoid fevers in Benghazi, Libya, were 
resistant to chloramphenicol, ampicillin, TMZ-SMZ, 
cephalosporin and gentamicin [46]. 
A contribution on the efficacy of pefloxacin in 
the treatment of typhoid fever was reported in 
Algeria in 1990 in patients with S. Typhi, indicating 
that a seven-day treatment of 400 mg of this 
quinolone twice a day provides a good alternative to 
the treatment of this disease  [67]. In Egypt, Girgis et 
al. [68] reported that one gram of azithromycin orally 
administered once on the first day, followed by 500 
mg given orally once daily for the next six days or 
500 mg of ciprofloxacin orally twice daily for seven 
days were both clinically and bacteriologically 
effective against typhoid fever caused by both 
susceptible and MDR S. Typhi strains. Azithromycin 
and ciprofloxacin are expensive drugs and usually not 
available in rural and semi-urban areas of some North 
African countries [69, KS Ghenghesh, unpublished 
observation]. Furthermore, resistance to ciprofloxacin 
among S. Typhi and S. Paratyphi B has recently been 
reported from Libya [46]. However, recent studies 
from Egypt observed the re-emergence of 
chloramphenicol and ampicillin susceptibility and 
therefore suggest the reintegration of these drugs for 
the treatment of typhoid fever in Egypt [70]. Their 
cheaper cost and availability in the developing 
countries, in addition to their well-established clinical 
efficiency, are among the benefits of reusing 
chloramphenicol and ampicillin [71]. In the future, 
studies are needed to determine whether the 
reintegration of these drugs can be applied to other 
countries of North Africa for treatment of typhoid 
fever. Collection of data that document antibiotic 
resistance patterns in the Mediterranean North 
African region is essential, and treatment of infection 
should be according to the current patterns of 
resistance. 
 
Typhoid fever vaccines 
Worldwide, two vaccines are currently licensed 
and widely used. The first is based on purified Vi 
antigen and is administered as one dose either 
intramuscularly or subcutaneously.  The Vi vaccine 
provides protection for at least three years but is not 
recommended for use in infants and so is not used to 
vaccinate children less than two years of age. The 
second is based on the attenuated S. typhi strain 
Ty21a that lacks both a functional galactose-
epimerase (galE) gene and the Vi antigen [72]. The 
Ty21a vaccine is administered orally in a three-dose 
regimen and provides protection for five to seven 
years. The vaccine was extensively tested in 
Alexandria, Egypt, where the liquid formulation 
showed 96% protection for three years [73]. Both 
vaccines have been endorsed by the WHO’s Strategic 
Advisory Group of Experts (SAGE) on immunization 
for their safety, efficacy and affordability, and for use 
in immunization of school-aged and/or preschool-
aged children [74]. 
There is no published data on whether or not 
these vaccines were used in the Mediterranean North 
Africa countries. Because typhoid fever incidence in 




most of the Mediterranean North Africa countries 
falls in the medium range and outbreaks are 
infrequent, the need to incorporate typhoid vaccine in 
the vaccination program in such countries may not be 
needed.  However, in some villages and localities 
within these countries that have poor sanitation 
systems and are without safe drinking water, typhoid 
vaccination may have a role in controlling the 
disease. In addition, typhoid fever vaccines can be 
used in the control of outbreaks as recommended by 
the WHO [72].  
In conclusion, typhoid and paratyphoid fever are 
endemic in the Mediterranean North African 
countries and MDR is common among S. Typhi and 
S. Paratyphi isolated in this region. To clarify the 
typhoid and paratyphoid fever situation in the North 
African Region, population-based studies are still 
needed. The information that will be gathered from 
these studies will support and assist the decision 
makers and health authorities in the region in the 
prevention and control of such important diseases. 
Finally, there is an urgent need to enhance the 
Salmonella surveillance not only in a single country 
but at the level of all Mediterranean North African 
Countries with a creation of a common collaboration 
strategy to defeat salmonellosis and in particular 
enteric fever in the region. 
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